# Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

> **NCT06099990** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 660 (estimated)

## Conditions studied

- High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
- **DRUG:** placebo; abiraterone acetate tablets; prednisone tablets

## Key facts

- **NCT ID:** NCT06099990
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 660 (ESTIMATED)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06099990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06099990, "Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06099990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*